Gestational MAM (Methylazoxymethanol) administration: A promising animal model for psychosis onset

Gwenaëlle Le Pen, Alfredo Bellon, Marie Odile Krebs, Thérèse M. Jay

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

This chapter provides an overview on exposure to methylazoxymethanol (MAM) at embryonic day 17 as a promising animal model for schizophrenia that mimics behavioral abnormalities and deficits in prefrontal cortex networks. This early insult produces in adult offspring from E17 MAM-treated dams the following: (1) behavioral changes including spontaneous hyperactivity and hypersensitivity to psychotomimetic drugs that are reminiscent of positive symptoms of schizophrenia and associated with a temporal pattern of expression; (2) impaired social interaction similar to that observed in schizophrenic patients existing prior to the onset of disease; (3) cognitive deficits in a variety of domain: working and reference memory, behavioral flexibility, attentional functioning, object recognition, and reversal learning; (4) behavioral abnormalities resembling schizophrenia-related endophenotypes like deficient sensorimotor gating and disrupted latent inhibition; (5) anatomical changes with cortical, thalamic, and hippocampal reductions in volume that are associated with an enlargement of the lateral ventricles; and (6) abnormalities in functional connectivity between brain areas that involve deficits in dopamine, glutamate, and GABA systems. The E17 MAM model that incorporates neuropathological and functional manifestations associated with schizophrenia may help forward early preventive interventions that can successfully reduce the risk of developing schizophrenia in exposed individuals.

Original languageEnglish (US)
Title of host publicationAnimal Models of Schizophrenia and Related Disorders
EditorsPatrick O'Donnell
Pages25-77
Number of pages53
DOIs
StatePublished - Jul 1 2011

Publication series

NameNeuromethods
Volume59
ISSN (Print)0893-2336
ISSN (Electronic)1940-6045

Keywords

  • anatomical and functional abnormalities
  • animal model
  • behavioral and cognitive deficits
  • hippocampus
  • MAM
  • prefrontal cortex
  • schizophrenia
  • schizophrenia-related endophenotypes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuroscience(all)
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Gestational MAM (Methylazoxymethanol) administration: A promising animal model for psychosis onset'. Together they form a unique fingerprint.

  • Cite this

    Le Pen, G., Bellon, A., Krebs, M. O., & Jay, T. M. (2011). Gestational MAM (Methylazoxymethanol) administration: A promising animal model for psychosis onset. In P. O'Donnell (Ed.), Animal Models of Schizophrenia and Related Disorders (pp. 25-77). (Neuromethods; Vol. 59). https://doi.org/10.1007/978-1-61779-157-4_2